Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs ... Dec 23
The pharma company continues to plan for a mid-2021 launch of JZP-458 following completion of the BLA submission and US FDA review and ... Dec 23
-Advertisements-